Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.
PaperCitations, authors & open-access status
Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 6 citations, 2010 year and closed oa status.
6
Citations
2010
Year
closed
OA Status